The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

The cost effectiveness organisation has published a draft evidence report on the first-in-class TSLP inhibitor – which is currently under FDA review ... allergic asthma, and with Dupixent ...

A Wisconsin couple is suing Walgreens and a pharmacy benefits company alleging their son died because he couldn't afford a ...

Shanon and William Schmidtknecht, of Poynette, say their 22-year-old son Cole was told the cost had jumped from $66 to $539 ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Get Instant Summarized Text (Gist) Asthma and antibiotic use at the time of initial endoscopic sinus surgery increase the likelihood of nasal polyp recurrence, necessitating revision surgery. Age ...

The Nose Knows: Nasal Swab Detects Asthma Type in Kids Jan. 2, 2025 — A new, non-invasive nasal swab test for kids that diagnoses specific asthma subtype, or endotype, could help clinicians ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Dexamphetamine—a restricted stimulant drug used to treat narcolepsy and Attention Deficient Hyperactivity Disorder ...